SMRT Inhibitors
MS-275, SNDX-275, Entinostat
- User: Male
- Hormonal: Non-Hormonal
-
Delivery type:
- Not Yet Determined
-
Intended Duration:
- Not Yet Determined
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Salk Institute for Biological Studies, University of California, Berkeley, University of California, Irvine, Utrecht University, University of Sydney
Details
- API: Not Yet Determined - Multiple Compounds in Development
- Target: SMRT
-
Mechanism of Action:
- Reduced Sperm Production
- Inactive Materials: Not Yet Determined
- Regimen: Not Yet Determined
- MPT: Not Potential MPT
- Promising Attributes: To be established - concept is in early development
Product Status
Active Pre-Clinical Development
History
According to research published in 2024, MS-275 is likely being tested in mice only as a proof-of-principle or tool compound to pharmacologically validate inhibition of SMRT as a male contraceptive strategy, but more specific lead compounds may be developed from it as a starting point.